326 related articles for article (PubMed ID: 20223661)
21. Thiophene substituted acylguanidines as BACE1 inhibitors.
Fobare WF; Solvibile WR; Robichaud AJ; Malamas MS; Manas E; Turner J; Hu Y; Wagner E; Chopra R; Cowling R; Jin G; Bard J
Bioorg Med Chem Lett; 2007 Oct; 17(19):5353-6. PubMed ID: 17761418
[TBL] [Abstract][Full Text] [Related]
22. Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors.
Nowak P; Cole DC; Aulabaugh A; Bard J; Chopra R; Cowling R; Fan KY; Hu B; Jacobsen S; Jani M; Jin G; Lo MC; Malamas MS; Manas ES; Narasimhan R; Reinhart P; Robichaud AJ; Stock JR; Subrath J; Svenson K; Turner J; Wagner E; Zhou P; Ellingboe JW
Bioorg Med Chem Lett; 2010 Jan; 20(2):632-5. PubMed ID: 19959359
[TBL] [Abstract][Full Text] [Related]
23. Application of fragment screening by X-ray crystallography to beta-secretase.
Murray CW; Callaghan O; Chessari G; Cleasby A; Congreve M; Frederickson M; Hartshorn MJ; McMenamin R; Patel S; Wallis N
J Med Chem; 2007 Mar; 50(6):1116-23. PubMed ID: 17315856
[TBL] [Abstract][Full Text] [Related]
24. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
[TBL] [Abstract][Full Text] [Related]
25. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
26. Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo.
Machauer R; Laumen K; Veenstra S; Rondeau JM; Tintelnot-Blomley M; Betschart C; Jaton AL; Desrayaud S; Staufenbiel M; Rabe S; Paganetti P; Neumann U
Bioorg Med Chem Lett; 2009 Mar; 19(5):1366-70. PubMed ID: 19195887
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological activity evaluation of BACE1 inhibitors with antioxidant activity.
Li HM; Yu SP; Fan TY; Zhong Y; Gu T; Wu WY; Zhao C; Chen Z; Chen M; Li NG; Wang XL
Drug Dev Res; 2020 Apr; 81(2):206-214. PubMed ID: 31397505
[TBL] [Abstract][Full Text] [Related]
28. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain.
Stockley JH; Ravid R; O'Neill C
FEBS Lett; 2006 Dec; 580(28-29):6550-60. PubMed ID: 17113083
[TBL] [Abstract][Full Text] [Related]
29. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
Stockley JH; O'Neill C
Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
[TBL] [Abstract][Full Text] [Related]
30. Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement.
Steele TG; Hills ID; Nomland AA; de León P; Allison T; McGaughey G; Colussi D; Tugusheva K; Haugabook SJ; Espeseth AS; Zuck P; Graham SL; Stachel SJ
Bioorg Med Chem Lett; 2009 Jan; 19(1):17-20. PubMed ID: 19036583
[TBL] [Abstract][Full Text] [Related]
31. Fragment-based discovery of BACE1 inhibitors using functional assays.
Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J
Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors.
Konno H; Sato T; Saito Y; Sakamoto I; Akaji K
Bioorg Med Chem Lett; 2015 Nov; 25(22):5127-32. PubMed ID: 26459211
[TBL] [Abstract][Full Text] [Related]
33. Glycosaminoglycan-induced activation of the beta-secretase (BACE1) of Alzheimer's disease.
Klaver DW; Wilce MC; Gasperini R; Freeman C; Juliano JP; Parish C; Foa L; Aguilar MI; Small DH
J Neurochem; 2010 Mar; 112(6):1552-61. PubMed ID: 20067575
[TBL] [Abstract][Full Text] [Related]
34. Beta-secretase as a target for the treatment of Alzheimer's disease.
Citron M
J Neurosci Res; 2002 Nov; 70(3):373-9. PubMed ID: 12391600
[TBL] [Abstract][Full Text] [Related]
35. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
[TBL] [Abstract][Full Text] [Related]
36. Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase.
Barrow JC; Stauffer SR; Rittle KE; Ngo PL; Yang Z; Selnick HG; Graham SL; Munshi S; McGaughey GB; Holloway MK; Simon AJ; Price EA; Sankaranarayanan S; Colussi D; Tugusheva K; Lai MT; Espeseth AS; Xu M; Huang Q; Wolfe A; Pietrak B; Zuck P; Levorse DA; Hazuda D; Vacca JP
J Med Chem; 2008 Oct; 51(20):6259-62. PubMed ID: 18811140
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
Geschwindner S; Olsson LL; Albert JS; Deinum J; Edwards PD; de Beer T; Folmer RH
J Med Chem; 2007 Nov; 50(24):5903-11. PubMed ID: 17985861
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
40. Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors.
Malamas MS; Barnes K; Johnson M; Hui Y; Zhou P; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Pangalos M; Reinhart P; Robichaud AJ
Bioorg Med Chem; 2010 Jan; 18(2):630-9. PubMed ID: 20045648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
